EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study

Jean-Sébastien Frenel, Laurent Mathiot, Claire Cropet, Edith Borcoman, Alice Hervieu, Elodie Coquan, Thibault De La Motte Rouge, Esma Saada-Bouzid, Renaud Sabatier, Pernelle Lavaud, Marta Jimenez, François Legrand und 3 weitere

Journal for ImmunoTherapy of Cancer · 2025-01 · 13 (1) · e010708

DOI: 10.1136/jitc-2024-010708 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.01.2025. Verfasst von Jean-Sébastien Frenel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France Jean-Sebastien.Frenel@ico.unicancer.fr. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Vinorelbine, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ligue Contre le Cancer, Institut National Du Cancer, AstraZeneca France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The MOVIE phase I/II trial ( NCT03518606 ) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort.

Methods

Patients received tremelimumab (intravenously, 75 mg, every four weeks (Q4W); four cycles max) plus durvalumab (intravenously, 1,500 mg, Q4W; 26 cycles max) and metronomic oral vinorelbine (40 mg, every three weeks (3QW)) until disease progression. The primary efficacy endpoint was the clinical benefit rate (CBR) based on the Response Evaluation Criteria in Solid Tumors V.1.1, which was analyzed using a Bayesian approach Results A total of 31 patients were enrolled and treated in the cervical cancer cohort. The median number of previous lines of chemotherapy for advanced disease was 2 (0–6), with all (100%) and 12 (38.7%) patients pretreated with cisplatin and bevacizumab, respectively. At the data cut-off, the median follow-up duration was 12.8 (Q1–Q3, 6.1–34.6) months. The CBR was 53.1% (95% CI, 36.0% to 69.8%), using a non-informative prior distribution (beta(1, 1)). The overall response rate was 41.9%, five patients achieved a complete response (16.1%), and eight patients (25.8%) had a partial response irrespective of histological subtype or programmed death-ligand 1 (PD-L1) expression. Of the 31 patients, 28 (90.3%) experienced treatment-related adverse events (TRAEs), 13 (41.9%) reported grade ≥3 immune-related adverse events (AEs), and 13 (41.9%) reported grade ≥3 chemotherapy-related AEs. The definitive discontinuation rate due to TRAEs was 16.1%.

Conclusions

Dual checkpoint blockade of PD-L1 and cytotoxic T-lymphocyte-associated antigen-4 combined with metronomic oral vinorelbine demonstrated meaningful and durable clinical activity in patients with previously treated advanced cervical cancer. Toxicity was significant but manageable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsVinorelbineAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalHumansFemaleMiddle AgedAdultAgedNeoplasm Recurrence, LocalAdministration, MetronomicAdministration, Oral

Stichwörter der Autor:innen

Cervical CancerChemotherapyImmune Checkpoint Inhibitor

Substanzen

durvalumabVinorelbinetremelimumabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France Jean-Sebastien.Frenel@ico.unicancer.fr.
  • Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
  • Department of Biostatistics, Centre Léon Bérard, Lyon, France.
  • Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
  • Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
  • Department of Medical Oncology, Centre François Baclesse, Caen, France.

Förderung

  • Ligue Contre le Cancer
  • Institut National Du Cancer
  • AstraZeneca France
  • Fondation Pierre Fabre

Zitieren

APA

Frenel, J. S., Mathiot, L., Cropet, C., Borcoman, E., Hervieu, A., Coquan, E., De La Motte Rouge, T., Saada-Bouzid, E., Sabatier, R., Lavaud, P., Jimenez, M., Legrand, F., Le Saux, O., Charafe, E., & Gonçalves, A. (2025). Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study. Journal for ImmunoTherapy of Cancer, 13(1), e010708. https://doi.org/10.1136/jitc-2024-010708

Vancouver

Frenel JS, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E, et al. Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study. Journal for ImmunoTherapy of Cancer. 2025;13(1):e010708. doi:10.1136/jitc-2024-010708

BibTeX
@article{Frenel2025,
  author = {Frenel, Jean-Sébastien and Mathiot, Laurent and Cropet, Claire and Borcoman, Edith and Hervieu, Alice and Coquan, Elodie and De La Motte Rouge, Thibault and Saada-Bouzid, Esma and Sabatier, Renaud and Lavaud, Pernelle and Jimenez, Marta and Legrand, François and Le Saux, Olivia and Charafe, Emmanuelle and Gonçalves, Anthony},
  title = {Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {1},
  pages = {e010708},
  doi = {10.1136/jitc-2024-010708}
}
Kostenlos starten →